EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost–Utility Analysis

Luca De Nicola iD, Filippo Aucella iD, Antonio De Pascalis iD, Giovanni Stallone, Massimiliano Povero iD, Linet A Odonde iD, Roberta Germanò, Chiara Ruotolo, Maria Serena Russo, Dario Troise iD, Loreto Gesualdo iD

Nutrients · 02.04.2026 · 18 (7) · 1142

DOI: 10.3390/nu18071142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, online erschienen am 02.04.2026. Verfasst von Luca De Nicola und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nephrologic Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Diet, Protein-Restricted, Cost-Benefit Analysis, Renal Insufficiency, Chronic, Dietary Supplements. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fresenius Kabi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Chronic kidney disease (CKD) is associated with substantial clinical and economic burden, largely driven by progression to dialysis. Nutritional interventions have shown potential in delaying disease progression, yet evidence on their cost-effectiveness remains limited. This study evaluated the long-term cost–utility profile of a low-protein diet supplemented with ketoanalogues (s-LPD) versus a standard low-protein diet (LPD) in patients with stage 4+ CKD from both the Italian National Health System (NHS) and societal perspectives.

Methods

A Markov model with monthly cycles simulated disease progression from pre-dialysis to dialysis or death. Clinical inputs were derived from the published literature, while costs reflected 2024 Italian tariffs. Three effectiveness scenarios (optimistic, conservative, and pessimistic) were explored to account for uncertainty in the treatment effect. Outcomes included costs, life-years, quality-adjusted life-years (QALYs), and incremental cost–utility ratios. Deterministic and probabilistic sensitivity analyses assessed model robustness.

Results

Across all scenarios, s-LPD improved survival (up to +0.59 life-years), increased QALYs (up to +0.48), and delayed dialysis initiation (up to +2.88 years) compared with LPD. From the NHS perspective, s-LPD was dominant in the optimistic scenario and cost-effective in both conservative and pessimistic scenarios, with cost savings or only a marginal cost that increases under extreme assumptions. Probabilistic sensitivity analyses confirmed a high probability of cost-effectiveness across scenarios. Results remained robust in additional scenario analyses, including the societal perspective.

Conclusions

This first Italian cost–utility analysis of s-LPD highlights that s-LPD is a cost-effective strategy for patients with advanced CKD, offering clinically meaningful benefits while reducing or containing healthcare costs. These findings support the adoption of s-LPD as part of conservative management strategies aimed at safely delaying dialysis initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, Protein-RestrictedCost-Benefit AnalysisRenal Insufficiency, ChronicDietary SupplementsKeto AcidsHumansItalyQuality-Adjusted Life YearsCost-Effectiveness AnalysisMarkov ChainsDisease ProgressionFemaleMaleRenal DialysisMiddle AgedAged

Stichwörter der Autor:innen

chronic kidney diseasecost-effectivenessdialysisketoanalogueslow-protein diet

Substanzen

Keto Acids

Autor:innen und Institutionen

  • Nephrologic Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Struttura Complessa di Nefrologia e Dialisi, Fondazione Casa Sollievo della Sofferenza, IRCCS, 71013 San Giovanni Rotondo, Italy.
  • UOC Nefrologia e Dialisi, Ospedale VITO FAZZI, 73100 Lecce, Italy.
  • Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
  • AdRes, 10155 Turin, Italy.
  • Unit of Nephrology, Dialysis and Transplantation, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.

ORCID-Profile: Luca De Nicola, Filippo Aucella, Antonio De Pascalis, Massimiliano Povero, Linet A Odonde, Dario Troise, Loreto Gesualdo

Förderung

  • Fresenius Kabi

Zitieren

APA

De Nicola, L., Aucella, F., De Pascalis, A., Stallone, G., Povero, M., Odonde, L. A., Germanò, R., Ruotolo, C., Russo, M. S., Troise, D., & Gesualdo, L. (2026). Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost–Utility Analysis. Nutrients, 18(7), 1142. https://doi.org/10.3390/nu18071142

Vancouver

De Nicola L, Aucella F, De Pascalis A, Stallone G, Povero M, Odonde LA, et al. Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost–Utility Analysis. Nutrients. 2026;18(7):1142. doi:10.3390/nu18071142

BibTeX
@article{DeNicola2026,
  author = {De Nicola, Luca and Aucella, Filippo and De Pascalis, Antonio and Stallone, Giovanni and Povero, Massimiliano and Odonde, Linet A and Germanò, Roberta and Ruotolo, Chiara and Russo, Maria Serena and Troise, Dario and Gesualdo, Loreto},
  title = {Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost–Utility Analysis},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1142},
  doi = {10.3390/nu18071142}
}
Kostenlos starten →